Laboratory of B Cell Neoplasia, Division of Molecular Oncology, San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Milano 20132, Italy.
Hematol Oncol Clin North Am. 2013 Apr;27(2):251-65. doi: 10.1016/j.hoc.2013.01.004.
Monoclonal B-cell lymphocytosis (MBL) is defined as a clonal B-cell expansion whereby the B-cell count is less than 5 × 10(9)/L and no symptoms or signs of lymphoproliferative disorders are detected. Based on B-cell count, MBL is further divided into low-count and clinical MBL. While low-count MBL seems to carry relevance mostly from an immunological perspective, clinical MBL and chronic lymphocytic leukemia appear to be overlapping entities. Only a deeper knowledge of molecular pathways and microenvironmental influences involved in disease evolution will help to solve the main clinical issue, i.e. how to differentiate nonprogressive and progressive cases requiring intensive follow-up.
单克隆 B 细胞淋巴增生症(MBL)定义为克隆性 B 细胞增殖,此时 B 细胞计数小于 5×10(9)/L,且未检测到淋巴增生性疾病的症状或体征。根据 B 细胞计数,MBL 进一步分为低计数和临床 MBL。虽然低计数 MBL 似乎主要从免疫学角度具有相关性,但临床 MBL 和慢性淋巴细胞白血病似乎是重叠的实体。只有更深入地了解疾病演变中涉及的分子途径和微环境影响,才能有助于解决主要的临床问题,即如何区分不需要强化随访的非进展性和进展性病例。